An official website of the United States government
Publication Information
Affiliation
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA.
Authors
Apodaca MC, Bacon B, Bashirova A, Bonkovsky HL, Carrington M, Chanock SJ, Chung RT, Cormier M, Crenshaw AT, Curto TM, Davis GL, DeSanto J, Di Bisceglie AM, Dienstag JL, Di Giammarino L, Dotrang M, Elbein R, Everson GT, Fontana RJ, Garcia-Tsao G, Ghany MG, Giansiracusa D, Goodman ZD, Gretch DR, HALT-C Trial Group, Haynes-Williams V, Hoefs JC, Hofmann C, Hoofnagle JH, Hutchinson AA, Jamal MM, Jones CB, Kelley M, King D, Kutner M, Lee WM, Lemon SM, Liang TJ, Lindsay KL, Lok AS, McKinley C, Milstein SL, Molchen WA, Morgan TR, Morishima C, Naishadham D, Neuschwander-Tetri B, O'Brien TR, Park C, Park Y, Perrillo RP, Pfeiffer RM, Reid AE, Richtmyer PA, Rivera E, Robuck PR, Seeff LB, Shelton J, Shiffman ML, Smith P, Snow KK, Sterling RK, Szabo G, Welzel TM, Wright EC
Studies
Citation
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR, HALT-C Trial Group. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009 Jun;49(6):1847-58.Abstract
Combination treatment with pegylated-interferon-alpha (PEG IFN-alpha) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may affect antiviral responses, we analyzed the relationship between variants in these genes and SVR among participants in the Hepatitis C Antiviral Long-Term treatment Against Cirrhosis (HALT-C) trial. Patients had advanced chronic hepatitis C that had previously failed to respond to interferon-based treatment. Participants were treated with peginterferon-alpha2a and ribavirin during the trial. Subjects with undetectable HCV RNA at week 72 were considered to have had an SVR. Subjects with detectable HCV RNA at week 20 were considered nonresponders. We used TaqMan assays to genotype 56 polymorphisms found in 13 genes in the interferon-alpha pathway. This analysis compares genotypes for participants with an SVR to nonresponders. The primary analysis was restricted to European American participants because a priori statistical power was low among the small number (n = 131) of African American patients. We used logistic regression to control the effect of other variables that are associated with treatment response. Among 581 European American patients, SVR was associated with IFNAR1 IVS1-22G (adjusted odds ratio, 0.57; P = 0.02); IFNAR2 Ex2-33C (adjusted odds ratio, 2.09; P = 0.02); JAK1 IVS22+112T (adjusted odds ratio, 1.66; P = 0.04); and ADAR Ex9+14A (adjusted odds ratio, 1.67; P = 0.03). For the TYK2-2256A promoter region variant, a borderline association was present among European American participants (OR, 1.51; P = 0.05) and a strong relationship among African American patients; all 10 with SVR who were genotyped for TYK2 -2256 carried the A variant compared with 68 of 120 (57%) nonresponders (P = 0.006).